echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Neuro Oncol: MEK-1/2 inhibitor selumetinib significantly improves the prognosis of recurrent/progressive low-grade glioma in children

    Neuro Oncol: MEK-1/2 inhibitor selumetinib significantly improves the prognosis of recurrent/progressive low-grade glioma in children

    • Last Update: 2021-03-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Childhood low-grade gliomas (pLGGs) are the most common brain tumors in children .


    Children's low-grade gliomas (pLGGs) are the most common brain tumors in children Children's low-grade gliomas (pLGGs) are the most common brain tumors inchildren

    Recently, researchers have prioritized the functional prognosis of children with low-grade glioma.


     

    This article reports the results of a PBTC Phase 2 trial in children with relapsed/progressive OPHGs, which evaluated the efficacy of the MEK-1/2 inhibitor selumetinib (selumetinib, AZD6244, ARRY-142886) in such patients.


    A total of 25 evaluable patients with multiple conditions were included in the analysis, and the median number of previous treatment courses was 4 (1-11).


    6 patients (24%) achieved partial remission, 14 (56%) had stable disease, 6 (24%) had partial remission, and 14 (56%) had stable disease.


    The 2-year PFS is 78±8.


    The 2-year PFS is 78±8.


    In summary, smetinib is well tolerated in children with relapsed/progressive OPHGs.


    Sumetinib is well tolerated in children with relapsed/progressive OPHGs, and it can also improve imaging remission, PFS and visual prognosis, and prolong the stable period of disease.


    Original source:

    Fangusaro Jason, Onar-Thomas Arzu, Poussaint Tina Young et al.


    oup.
    com/neuro-oncology/advance-article-abstract/doi/10.
    1093/neuonc/noab047/6149924?redirectedFrom=fulltext">A Phase 2 Trial of Selumetinib in Children with Recurrent Optic Pathway and Hypothalamic Low-Grade Glioma without NF1: A Pediatric Brain Tumor Consortium Study in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.